الفهرس Only 14 pages are availabe for public view
 |  | from | 167 |  |  |
| | | from | 167 | | |
Abstract
Background: Plasminogen activator inhibitor (PAI-1) is a regulatory enzyme of fibrinolytic system. Point mutation in PAI-1 is implicated in the pathogenesis of diabetic nephropathy (DN) in many ethinic groups. The aim of this study was to study the association of 4G/5G PAI-1 polymorphism as a risk factor of DN in type 2 diabetes mellitus (T2DM) patients. Subjects and Methods: The PAI-1 polymorphism was detected in 90 T2DM patients by SSP-PCR. They were divided into 2 groups: 45 patients without nephropathy, 45 patients with nephropathy. Plasma levels of PAI-1 were assayed by ELISA. Results: The genomic DNA analysis of (PAI-1) 4G/5G gene polymorphism (rs 1799889) revealed no statistically significant difference in distribution of different genotypes (P=1.0). The frequency of4G/4G genotype was (8.9 % & 11.1%), 4G/5G genotype was (48.9 % & 48.9 %) and 5G/5G genotype was (42.2% & 40%) in group I (diabetic patients without nephropathy) and group II (diabetic patients with nephropathy) respectively. Plasma levels of PAI-1 were not associated with PAI-1 mutation, also there was no significant association between PAI-1 level and DN (P=0.548). Conclusion: Plasminogen activator inhibitor-1 gene mutation was not associated with increased risk for diabetic nephropathy in type 2 diabetic patients and had no effect on plasma levels of PAI-1